Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uniparental Disomy | 9 | 2023 | 49 | 3.480 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2019 | 723 | 1.000 |
Why?
|
| Neoplasms | 5 | 2022 | 2792 | 0.910 |
Why?
|
| Papillomavirus Infections | 2 | 2019 | 294 | 0.880 |
Why?
|
| Ovarian Neoplasms | 2 | 2019 | 419 | 0.850 |
Why?
|
| Isochromosomes | 1 | 2022 | 18 | 0.770 |
Why?
|
| Biomarkers, Tumor | 3 | 2017 | 1498 | 0.750 |
Why?
|
| WT1 Proteins | 3 | 2013 | 27 | 0.720 |
Why?
|
| Genome-Wide Association Study | 5 | 2019 | 1687 | 0.670 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 351 | 0.650 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2017 | 881 | 0.650 |
Why?
|
| Breast Neoplasms | 6 | 2013 | 2512 | 0.630 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 667 | 0.600 |
Why?
|
| Receptor, ErbB-2 | 4 | 2013 | 515 | 0.590 |
Why?
|
| Alleles | 2 | 2022 | 1615 | 0.580 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2017 | 7 | 0.550 |
Why?
|
| Alcohol Drinking | 1 | 2019 | 343 | 0.520 |
Why?
|
| Papillomaviridae | 1 | 2017 | 144 | 0.510 |
Why?
|
| DNA, Viral | 1 | 2017 | 480 | 0.490 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2015 | 52 | 0.460 |
Why?
|
| Genes, Wilms Tumor | 1 | 2013 | 8 | 0.440 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 1662 | 0.420 |
Why?
|
| RNA, Neoplasm | 1 | 2013 | 138 | 0.420 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2013 | 80 | 0.420 |
Why?
|
| Smoking | 1 | 2019 | 1049 | 0.420 |
Why?
|
| Neoplasm Staging | 4 | 2019 | 1275 | 0.410 |
Why?
|
| Neoplasm Grading | 3 | 2019 | 272 | 0.410 |
Why?
|
| Inheritance Patterns | 1 | 2012 | 127 | 0.390 |
Why?
|
| Prognosis | 6 | 2019 | 4637 | 0.390 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 341 | 0.380 |
Why?
|
| Homozygote | 3 | 2023 | 547 | 0.350 |
Why?
|
| Mutation | 5 | 2019 | 5849 | 0.350 |
Why?
|
| Sarcoma | 1 | 2012 | 182 | 0.340 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2019 | 2634 | 0.340 |
Why?
|
| Genomics | 2 | 2019 | 1501 | 0.330 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2017 | 1893 | 0.310 |
Why?
|
| MicroRNAs | 1 | 2015 | 835 | 0.310 |
Why?
|
| Genome, Human | 2 | 2012 | 1272 | 0.300 |
Why?
|
| Gene Expression Profiling | 4 | 2019 | 1711 | 0.270 |
Why?
|
| Receptors, Estrogen | 1 | 2010 | 795 | 0.270 |
Why?
|
| Databases, Genetic | 2 | 2019 | 474 | 0.270 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 878 | 0.260 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 1756 | 0.260 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 2169 | 0.230 |
Why?
|
| Humans | 17 | 2023 | 125090 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 1054 | 0.210 |
Why?
|
| Epigenesis, Genetic | 2 | 2017 | 676 | 0.180 |
Why?
|
| Sequence Deletion | 1 | 2023 | 525 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2015 | 369 | 0.180 |
Why?
|
| Gain of Function Mutation | 1 | 2019 | 106 | 0.160 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2012 | 1016 | 0.150 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 149 | 0.150 |
Why?
|
| Female | 9 | 2019 | 66748 | 0.150 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 900 | 0.140 |
Why?
|
| Virus Integration | 1 | 2017 | 42 | 0.140 |
Why?
|
| Middle Aged | 4 | 2019 | 26918 | 0.140 |
Why?
|
| Cell Transformation, Viral | 1 | 2017 | 106 | 0.130 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2017 | 131 | 0.130 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1357 | 0.130 |
Why?
|
| Lung | 1 | 2023 | 1498 | 0.120 |
Why?
|
| Epigenomics | 1 | 2015 | 164 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2015 | 103 | 0.120 |
Why?
|
| Datasets as Topic | 1 | 2015 | 89 | 0.120 |
Why?
|
| Host-Pathogen Interactions | 1 | 2017 | 253 | 0.110 |
Why?
|
| Survival Rate | 1 | 2019 | 2061 | 0.110 |
Why?
|
| RNA Isoforms | 1 | 2013 | 6 | 0.110 |
Why?
|
| Aged | 3 | 2019 | 19858 | 0.110 |
Why?
|
| MCF-7 Cells | 1 | 2013 | 222 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2013 | 1101 | 0.100 |
Why?
|
| Centromere | 1 | 2012 | 107 | 0.100 |
Why?
|
| Chromosomes, Human | 1 | 2012 | 128 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2011 | 49 | 0.090 |
Why?
|
| Telomere | 1 | 2012 | 213 | 0.090 |
Why?
|
| Adult | 3 | 2019 | 29627 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2013 | 868 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 1290 | 0.090 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 358 | 0.090 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 794 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 725 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2012 | 319 | 0.080 |
Why?
|
| Chromosome Deletion | 1 | 2012 | 647 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2011 | 779 | 0.080 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 124 | 0.080 |
Why?
|
| Computational Biology | 1 | 2012 | 810 | 0.070 |
Why?
|
| Apoptosis | 2 | 2005 | 1806 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2013 | 2821 | 0.070 |
Why?
|
| Chromosome Disorders | 1 | 2009 | 311 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2012 | 1002 | 0.060 |
Why?
|
| Cell Division | 2 | 2005 | 781 | 0.060 |
Why?
|
| Cyclin D | 1 | 2005 | 6 | 0.060 |
Why?
|
| S Phase | 1 | 2005 | 73 | 0.060 |
Why?
|
| Cyclins | 1 | 2005 | 101 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2017 | 4534 | 0.060 |
Why?
|
| Fenretinide | 1 | 2004 | 16 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 83 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2004 | 232 | 0.050 |
Why?
|
| Phenotype | 1 | 2012 | 4263 | 0.050 |
Why?
|
| Male | 2 | 2019 | 61470 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 3156 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2005 | 3348 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 6596 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2002 | 698 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 1694 | 0.030 |
Why?
|
| Animals | 1 | 2012 | 34220 | 0.020 |
Why?
|
| Nitrobenzenes | 1 | 2004 | 19 | 0.010 |
Why?
|
| Dinoprost | 1 | 2004 | 28 | 0.010 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 59 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2004 | 57 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 155 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2004 | 270 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2002 | 78 | 0.010 |
Why?
|
| Liposomes | 1 | 2002 | 188 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2004 | 489 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2002 | 363 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2002 | 256 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2004 | 492 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 1064 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 546 | 0.010 |
Why?
|
| Estradiol | 1 | 2002 | 532 | 0.010 |
Why?
|
| Cell Line | 1 | 2002 | 2758 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2004 | 1526 | 0.010 |
Why?
|